secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001213900-24-113467
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Raphael Pharma reports positive proof-of-concept study of cannabinoid formula in RA
--------------------------------------------------------------------------------

- DAS28 score reduced by 19.2%, moving from high to moderate disease activity in 12 patients.
- Participants in remission increased from 0% at baseline to 16.67% at week 8.
- Pain levels dropped from 75% reporting negative result to 50%; morning stiffness from 75% to 41.67%.
- 91.7% of participants would recommend Raphael's Formula to others with RA; 83.3% willing to continue use.
- Blood biomarkers showed no statistically significant changes, but overall symptom management improved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390024113467/0001213900-24-113467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390024113467/ea0226291-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-113467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer